昱厚生技

Yuho Biomedical is a clinical-stage biotechnology company based in Taiwan that focuses on the development of mucosal vaccines and immunotherapies. The company's core technology is the LTh(α) platform, a proprietary protein-based mucosal adjuvant derived from a modified heat-labile enterotoxin of E. coli. This platform is designed to enhance immune responses at mucosal surfaces, enabling the delivery of treatments via nasal spray to induce both systemic and local immunity. Yuho's clinical pipeline includes candidates for COVID-19, influenza, and allergic rhinitis, with several programs currently in Phase 2 trials. By leveraging its unique adjuvant technology, the company aims to provide more effective and less invasive solutions for infectious diseases and allergic conditions.